HAS3 and cholangiocarcinoma: Conversely, HAS3 exhibited significant upregulation in CESC, cholangiocarcinoma (CHOL), esophageal carcinoma (ESCA), HNSC, KIRC, KIRP, LIHC, LUSC, pheochromocytoma and paraganglioma (PCPG), and UCEC tumors.